MedPath

Use of neuromuscular monitor to assess intubating conditions

Completed
Conditions
18 to 60 yearseither sexASA I and II
Registration Number
CTRI/2016/10/007419
Lead Sponsor
Lady Hardinge Medical College
Brief Summary

Neuromuscularblockers (NMBs) are widely used in anaesthesia practice during endotrachealintubation. The degree of neuromuscular block is usually evaluated by clinicalcriteria. But the recommendation for application of neuromuscular monitoring topatients receiving NMBs is based on two important issues: first, on thevariable individual response to muscle relaxants and second because of thenarrow therapeutic window. Adequate muscle relaxation  for intubation corresponds to a narrow rangeof 90 to 95% receptor occupancy.1 Inadequate muscle relaxationduring intubation can lead to difficulty in securing the airway or multipleattempts leading to laryngeal morbidity like postoperative hoarseness (4-42%)and vocal cord injury.2

Rocuroniumis one of the most commonly used non depolarising muscle relaxant forintubation of the trachea. It has been postulated that laryngeal muscles beingresistant to the effects of neuromuscular blocking agents,3 requireat least twice the ED95 dose.4

Asit is difficult to quantify the relaxation of the laryngeal muscles, thereforesurrogates such as Adductor pollicis longus (APL), orbicularis oculi (OO),corrugator supercilii (CS)5 and even flexor hallucis brevis (FHB)6have been utilised, though APL is the preferred site. Neuromuscular transmissioncan be monitored by various methods like single twitch (ST), double burststimulation (DBS) and train of four (TOF). Although good clinical researchpractice (GCRP) states that either ST or TOF can be used as a guide forintubation, TOF is preferable because it is more sensitive to lesser degree ofreceptor occupancy than single twitch.1 Observation of evoked TOFresponses after a dose of non depolarising muscle relaxant allows prediction of onset time of paralysis oflaryngeal muscles  in individualpatients.

Inthe absence of availability of NMT monitors, timed intubation has beenpracticed. However, patient factors1 such as age, gender,7medical condition (ASA physical status), body weight affect thepharmacokinetics and pharmacodynamics of the drug.

Onreviewing the literature, we found that although, clinically acceptableconditions have been obtained with rocuronium 0.6mg/kg in 90 seconds, therehave not been many studies to quantify the proportion of patients havingexcellent conditions and time required thereof for a standard observableendpoint i.e, disappearance of either three (T1) or all twitches (T0) after aTOF stimulus. The literature does not indicate which endpoint provides the bestintubating conditions.

Thereforethere is a need to ascertain the percentage of healthy routine patientsachieving excellent intubating conditions and the time taken to achieve thesewith rocuronium 0.6mg/Kg using defined monitor i.e, TOF stimulation and associatedpost operative sore throat if any.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
250
Inclusion Criteria

1.Age 18 to 60 yrs of either sex 2.ASA physical status I and II 3.Planned for elective surgery under general anaesthesia receiving rocuronium 0.6 mg/Kg for endotracheal intubation.

Exclusion Criteria

1.Patient refusal to participate in the study 2.Patients with history of neuromuscular disease 3.Patients having anticipated difficult airway 4.Patients with BMI <20 and >30 5.Patients unable to converse in Hindi or English.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of patients having excellent intubating conditions with rocuronium 0.6mg/KgAfter endotracheal intubation
Secondary Outcome Measures
NameTimeMethod
a)Mean time to achieve T1 or T0b)Intubating conditions at T1 or T0

Trial Locations

Locations (1)

Main Operation theatre

🇮🇳

Delhi, DELHI, India

Main Operation theatre
🇮🇳Delhi, DELHI, India
Dr Deepa Rani
Principal investigator
8826599684
deeparani10220@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.